ETM
EBS icon

Euclidean Technologies Management’s Emergent Biosolutions EBS Stock Holding History

Euclidean Technologies Management’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-3,741
Closed -$236K – 90
2021
Q2 		$236K Buy
+3,741
New +$240K 0.19% 64

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SCM
Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return

Euclidean Technologies Management's EBS Position: Q3 2021 in Review

Euclidean Technologies Management sold out of Emergent Biosolutions (EBS) in Q3 2021, closing a stake of 3,741 shares — an estimated $236K sold.

Euclidean Technologies Management first reported a position in EBS in Q2 2021 and held it in 1 quarter. The position peaked at $236K in Q2 2021. 277 funds tracked by Wall St. Rank hold EBS as of Q3 2021.

  • Euclidean Technologies Management reported no remaining Emergent Biosolutions position as of Q3 2021 after selling out during the quarter.
  • Euclidean Technologies Management sold 3,741 Emergent Biosolutions shares in Q3 2021, an estimated $236K.
  • Euclidean Technologies Management first reported a position in Emergent Biosolutions in Q2 2021 and held it in 1 quarter.
  • Euclidean Technologies Management's Emergent Biosolutions position peaked at $236K in Q2 2021.
  • 277 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q3 2021.

Based on Euclidean Technologies Management's 13F filing for Q3 2021, filed 2 Nov 2021.